Hyperosmotic pretreatment reduces infarct size in the rat heart.
Preconditioning of the heart can be achieved by an ischemia/reperfusion stimulus, but also by stretching of the heart by an acute volume overload. Since manipulations of the extracellular osmolality affects cell size, we hypothesized that hyperosmotic pretreatment of the isolated perfused rat heart could reduce infarct size following regional ischemia (RI). Langendorff perfused rat hearts were subjected to 30 min RI by ligature of the main branch of the left coronary artery followed by 120 min reperfusion (control group). Ischemic preconditioning (IP-5') was achieved by 5 min total global ischemia and 5 min reperfusion prior to RI. Hyperosmotic pretreatment was accomplished by perfusion with a hyperosmotic buffer (600 mOsm/kg H2O by adding mannitol) for 1 min, 2 min or 5 min. At the end of the experiments, the hearts were cut into 2 mm slices, incubated with triphenyltetrazoliumchloride before scanning and computerized for estimation of infarct size. The average infarct size (as percentage of area at risk) in the control group was 42% and was significantly reduced to 16% by ischemic preconditioning and to 17% by 2 min hyperosmotic pretreatment. Neither 1 min nor 5 min hyperosmotic pretreatment reduced infarct size as compared to the controls. The infarct reducing effect of 2 min hyperosmotic pretreatment was not blunted by inhibition of protein kinase C (chelerytrine chloride), the Na+/H+-exchanger (HOE 694) or stretch-activated anion channels (gadolinium chloride). The results indicate that short-lasting hyperosmotic perturbations of the extracellular environment may precondition the heart to a subsequent ischemic insult.
Falck
G
G
Norwegian University of Science and Technology, Department of Physiology and Biomedical Engineering, Medisinsk Teknisk Senter, Trondheim. Geir.Falck@medisin.ntnu.no
Schjott
J
J
Jynge
P
P
D000470:Alkaloids; D000818:Animals; D053119:Benzophenanthridines; D005456:Fluorescent Dyes; D005682:Gadolinium / Q000494:pharmacology; D006146:Guanidines / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D008353:Mannitol / Q000494:pharmacology; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000517:prevention & control*; D015425:Myocardial Reperfusion; D009994:Osmolar Concentration; D010477:Perfusion; D010617:Phenanthridines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D012039:Regional Blood Flow; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D013450:Sulfones / Q000494:pharmacology; D013778:Tetrazolium Salts; D017725:Ventricular Pressure
D000470:Alkaloids; D053119:Benzophenanthridines; D005456:Fluorescent Dyes; D006146:Guanidines; D010617:Phenanthridines; D017923:Sodium-Hydrogen Exchangers; D013450:Sulfones; D013778:Tetrazolium Salts; C074107:3-methylsulfonyl-4-piperidinobenzoyl guanidine; D008353:Mannitol; C009591:triphenyltetrazolium; D005682:Gadolinium; C016299:chelerythrine; D011493:Protein Kinase C; C038958:gadolinium chloride